Information Provided By: 
Fly News Breaks for January 30, 2019
SYK
Jan 30, 2019 | 08:02 EDT
Canaccord analyst Kyle Rose noted Stryker reported Q4 results above expectations. The analyst views the company as a compelling asset and said new product cycles in medsurg and neurotech/spine further support fundamental momentum across its other markets. Rose reiterated his Buy rating and raised his price target to $190 from $185 on Stryker shares.
News For SYK From the Last 2 Days
